• Our Mission
    • Overview
    • Leadership
  • Science & Technology
    • CoreX™
    • AlloChem™
    • Mine™
  • Pipeline
  • Investors
    • Overview
    • Press Releases
    • Events & Presentations
    • SEDAR+ Filings
    • Stock Information
    • Leadership
    • Investor FAQ
    • Email Alerts

Sharp Therapeutics Corp. Reports Second Quarter 2025 Results and Expands Market Presence with Listing On OTCQB

Aug 29, 2025 | Press Releases

Pittsburgh, Pennsylvania and Toronto, Ontario–(Newsfile Corp. – August 29, 2025) – Sharp Therapeutics Corp. (TSXV: SHRX) (OTCQB: SHRXF) (“Sharp” or the “Company”) announces the release of its condensed interim...

Sharp Therapeutics Corp. Engages Rho Inc. to Help Advance Compounds into Clinical Trials for Gaucher Disease

Jul 29, 2025 | Press Releases

Pittsburgh, Pennsylvania and Toronto, Ontario–(Newsfile Corp. – July 29, 2025) – Sharp Therapeutics Corp. (TSXV: SHRX) (“Sharp” or the “Company”), a preclinical-stage biotechnology company developing small molecule...

Sharp Therapeutics Corp. Reports First Quarter 2025 Results

May 22, 2025 | Press Releases

Pittsburgh, Pennsylvania and Toronto, Ontario–(May 22, 2025) – Sharp Therapeutics Corp. (TSXV: SHRX) (“Sharp” or the “Company”), a pre-clinical-stage biotechnology company developing small molecule therapies to treat genetic...

Sharp Therapeutics Corp. Nominates Clinical Candidate for Gaucher's Disease

May 13, 2025 | Press Releases

Pittsburgh, Pennsylvania and Toronto, Ontario–(May 13, 2025) – Sharp Therapeutics Corp. (TSXV: SHRX) (“Sharp” or the “Company”), a pre-clinical-stage biotechnology company developing small molecule therapies to treat genetic...

STX Partners LLP and Newlin Investment Co. Exercise Warrants of Sharp Therapeutics Corp.

Apr 21, 2025 | Press Releases

Pittsburgh, Pennsylvania and Toronto, Ontario, April 21, 2025 — Sharp Therapeutics Corp. (“Sharp” or the “Company”) (TSX-V:SHRX), a pre-clinical-stage biotechnology company developing small molecule therapies to treat hereditary...

Sharp Therapeutics Corp. Completes Share Consolidation

Jan 27, 2025 | Press Releases

Pittsburgh, Pennsylvania and Toronto, Ontario–(January 27, 2025) – Sharp Therapeutics Corp. (TSXV: SHRX) (“Sharp” or the “Company”), a pre-clinical stage biotechnology company specializing in small molecule drugs to treat...
« Older Entries
Next Entries »

Recent Posts

  • Sharp Therapeutics Corp. Reports First Half 2026 Results and Development Update
  • Sharp Therapeutics Announces Closing of Non-Brokered Private Placement
  • Sharp Therapeutics Corp. Announces Results from Annual Meeting of Shareholders
  • Sharp Therapeutics Announces Non-Brokered Private Placement and Provides Operational Update
  • Sharp Therapeutics Announces Filing of Amended and Restated Management Information Circular and New Annual Meeting Date

Recent Comments

No comments to show.

Stay connected

  • Our Mission
    • Overview
    • Leadership
  • Science & Technology
    • CoreX™
    • AlloChem™
    • Mine™
  • Pipeline
  • Investors
    • Overview
    • Press Releases
    • Events & Presentations
    • SEDAR+ Filings
    • Stock Information
    • Leadership
    • Investor FAQ
    • Email Alerts
  • Follow
  • Follow
  • Follow

© Sharp Therapeutics Corp. All Rights Reserved.